{
  "id": 11425491,
  "title": "#EASD26: Regeneron sees a future combining its obesity drug with lipid-lowering therapy",
  "url": "https://urgent.news/2026/10/02/easd26-regeneron-sees-a-future-combining-its-obesity-drug-with-lipid",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-02T11:00:47.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/easd26-regeneron-sees-a-future-combining-its-obesity-drug-with-lipid-lowering-therapy/"
  },
  "original_language": "en",
  "account": null,
  "summary": "MILAN — As more GLP-1-based drugs reach late-stage trials and post stronger and stronger weight loss effects, companies that want to enter the market are looking for differentiating factors. Regeneron has hit on something new and ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}